RegMed XB Referenced in Wennink Report on the Future of Life Sciences & Biotechnology in the Netherlands

− 1 min read

The in December 2025 published independent advisory report chaired by Peter Wennink translates the findings of the Draghi report on Europe’s future earning capacity to the Dutch context.

The report identifies Life Sciences & Biotechnology as one of four strategic domains essential to safeguarding and strengthening the Netherlands’ long-term economic and societal impact.

Within this domain, the Biotech Nexus project proposal focuses on reinforcing the entire biotechnology value chain, with particular attention to innovation clusters around university medical centers. The goal is to achieve more consistent and successful commercialization of biomedical innovations.

A key component of Biotech Nexus is Advanced Therapy Medicinal Products (ATMPs), one of three designated biotech flagships. The ATMP program targets critical enablers such as clinical trials, manufacturing, vector development, and regulatory frameworks—aimed at accelerating the delivery of innovative therapies to patients and expanding patient access.

RegMed XB is pleased to be referenced both in the overarching Biotech Nexus proposal and on the dedicated ATMP page (appendix Project Proposals – Life Sciences & Biotechnology, pages 48 and 50, Dutch). This recognition reflects RegMed XB’s sustained contributions over recent years to ATMP and regenerative medicine valorization and translation activities, bringing together academia, health foundations, industry, and governmental organizations to accelerate the path from lab to patient.

The Wennink Report underscores that maintaining the Netherlands’ leading position in life sciences and biotechnology requires continued public investment alongside private capital. RegMed XB strongly supports the report’s conclusions and recommendations, particularly those related to Biotech Nexus and ATMP development, and looks forward to continued collaboration across the ecosystem to realize their full potential.

Excerpts shown are taken from the appendix “Project Proposals – Life Sciences & Biotechnology” (Wennink Report, December 2025). Full report links: https://www.rapportwennink.nl/bijlagen/